The specific VPAC2 agonist Bay 55-9837 increases neuronal damage and hemorrhagic transformation after stroke in type 2 diabetic rats

Neuropeptides

Volumn 47, Issue 2, 2013, Pages 133-137

  Darsalia, Vladimer ^a   Mansouri, Shiva ^a   Wolbert, Petra ^a   Barde, Swapnali ^a   Sjöholm, åke ^a   Patrone, Cesare ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Bay 55 9837; Diabetes; Goto Kakizaki (GK) rats; MCAO; Stroke; VIP; VPAC2

Indexed keywords

BAY 559837; GLUCOSE; HORMONE RECEPTOR STIMULATING AGENT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD SAMPLING; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CLINICAL ASSESSMENT; CONTROLLED STUDY; DIET RESTRICTION; DISEASE SEVERITY; DRUG EFFICACY; GLUCOSE BLOOD LEVEL; GLYCEMIC INDEX; LOW DRUG DOSE; MALE; MIDDLE CEREBRAL ARTERY OCCLUSION; NERVE CELL LESION; NEUROPROTECTION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; RAT; TREATMENT DURATION;

ANIMALS; BLOOD GLUCOSE; CELL COUNT; DIABETES MELLITUS, TYPE 2; DISEASE PROGRESSION; GLUCOSE TOLERANCE TEST; IMMUNOHISTOCHEMISTRY; INFARCTION, MIDDLE CEREBRAL ARTERY; INTRACRANIAL HEMORRHAGES; MALE; MIDDLE CEREBRAL ARTERY; NEURONS; PEPTIDE FRAGMENTS; RATS; RECEPTORS, VASOACTIVE INTESTINAL PEPTIDE, TYPE II; STROKE; VASOACTIVE INTESTINAL PEPTIDE;

RATTUS;

EID: 84875267631     PISSN: 01434179     EISSN: 15322785     Source Type: Journal    
DOI: 10.1016/j.npep.2012.08.008     Document Type: Article

References (44)

1. Arimura A. Perspectives on pituitary adenylate cyclase activating polypeptide (PACAP) in the neuroendocrine, endocrine, and nervous systems. Jpn. J. Physiol. 1998, 48:301-331.
2. Beauquis J., Homo-Delarche F., Giroix M.H., Ehses J., Coulaud J., Roig P., Portha B., De Nicola A.F., Saravia F. Hippocampal neurovascular and hypothalamic-pituitary-adrenal axis alterations in spontaneously type 2 diabetic GK rats. Exp. Neurol. 2010, 222:125-134.
3. Brenneman D.E. Neuroprotection: a comparative view of vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide. Peptides 2007, 28:1720-1726.
4. Cox C.P., Linden J., Said S.I. VIP elevates platelet cyclic AMP (cAMP) levels and inhibits in vitro platelet activation induced by platelet-activating factor (PAF). Peptides 1984, 5:325-328.
5. Delgado M., Varela N., Gonzalez-Rey E. Vasoactive intestinal peptide protects against beta-amyloid-induced neurodegeneration by inhibiting microglia activation at multiple levels. Glia 2008, 56:1091-1103.
6. Dickson L., Finlayson K. VPAC and PAC receptors: From ligands to function. Pharmacol. Ther. 2009, 121:294-316.
7. Ergul A., Elgebaly M.M., Middlemore M.L., Li W., Elewa H., Switzer J.A., Hall C., Kozak A., Fagan S.C. Increased hemorrhagic transformation and altered infarct size and localization after experimental stroke in a rat model type 2 diabetes. BMC Neurol. 2007, 7:33.
8. Fahrenkrug J. VIP and PACAP. Results Probl. Cell Differ. 2010, 50:221-234.
9. Gaede P., Vedel P., Larsen N., Jensen G.V., Parving H.H., Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N. Engl. J. Med. 2003, 348:383-393.
10. Ganea D., Rodriguez R., Delgado M. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide: players in innate and adaptive immunity. Cell Mol. Biol. (Noisy-le-grand) 2003, 49:127-142.
11. Ghanaat-Pour H., Sjoholm A. Gene expression regulated by pioglitazone and exenatide in normal and diabetic rat islets exposed to lipotoxicity. Diabetes Metab. Res. Rev. 2009, 25:163-184.
12. Grant S., Lutz E.M., McPhaden A.R., Wadsworth R.M. Location and function of VPAC1, VPAC2 and NPR-C receptors in VIP-induced vasodilation of porcine basilar arteries. J. Cereb. Blood Flow Metab. 2006, 26:58-67.
13. Haratz S., Tanne D. Diabetes, hyperglycemia and the management of cerebrovascular disease. Curr. Opin. Neurol. 2011, 24:81-88.
14. Harmar A.J., Arimura A., Gozes I., Journot L., Laburthe M., Pisegna J.R., Rawlings S.R., Robberecht P., Said S.I., Sreedharan S.P., Wank S.A., Waschek J.A. International Union of Pharmacology. XVIII. Nomenclature of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide. Pharmacol. Rev. 1998, 50:265-270.
15. Hoover D.B., Tompkins J.D., Parsons R.L. Differential activation of guinea pig intrinsic cardiac neurons by the PAC1 agonists maxadilan and pituitary adenylate cyclase-activating polypeptide 27 (PACAP27). J. Pharmacol. Exp. Ther. 2009, 331:197-203.
16. Ishizuka Y., Kashimoto K., Mochizuki T., Sato K., Ohshima K., Yanaihara N. Cardiovascular and respiratory actions of pituitary adenylate cyclase-activating polypeptides. Regul. Pept. 1992, 40:29-39.
17. Kazuyama E., Saito M., Kinoshita Y., Satoh I., Dimitriadis F., Satoh K. Endothelial dysfunction in the early- and late-stage type-2 diabetic Goto-Kakizaki rat aorta. Mol. Cell Biochem. 2009, 332:95-102.
18. Kim W.K., Kan Y., Ganea D., Hart R.P., Gozes I., Jonakait G.M. Vasoactive intestinal peptide and pituitary adenylyl cyclase-activating polypeptide inhibit tumor necrosis factor-alpha production in injured spinal cord and in activated microglia via a cAMP-dependent pathway. J. Neurosci. 2000, 20:3622-3630.
19. Koizumi J., Yoshida Y., Nakazawa T., Ooneda G. Experimental studies of ischemic brain edema. 1. A new experimental model of cerebral embolism in rats in which recirculation can be introduced in the ischemic area. Stroke 1986, 8:1-8.
20. Kruyt N.D., Biessels G.J., Devries J.H., Roos Y.B. Hyperglycemia in acute ischemic stroke: pathophysiology and clinical management. Nat. Rev. Neurol. 2010, 6:145-155.
21. Makela J., Koivuniemi R., Korhonen L., Lindholm D. Interferon-gamma produced by microglia and the neuropeptide PACAP have opposite effects on the viability of neural progenitor cells. PLoS One 2010, 5:e11091.
22. Mansouri S., Ortsater H., Pintor Gallego O., Darsalia V., Sjoholm A., Patrone C. Pituitary adenylate cyclase-activating polypeptide counteracts the impaired adult neural stem cell viability induced by palmitate. J. Neurosci. Res. 2012, 90:759-768.
23. Modlin I.M., Bloom S.R., Mitchell S.J. Experimental evidence for vasoactive intestinal peptide as the cause of the watery diarrhea syndrome. Gastroenterol. 1978, 75:1051-1054.
24. Moody T.W., Ito T., Osefo N., Jensen R.T. VIP and PACAP: recent insights into their functions/roles in physiology and disease from molecular and genetic studies. Curr. Opin. Endocrinol. Diab. Obes. 2011, 18:61-67.
25. Mutt V., Said S.I. Structure of the porcine vasoactive intestinal octacosapeptide. The amino-acid sequence. Use of kallikrein in its determination. Eur. J. Biochem. 1974, 42:581-589.
26. Nandha K.A., Benito-Orfila M.A., Smith D.M., Ghatei M.A., Bloom S.R. Action of pituitary adenylate cyclase-activating polypeptide and vasoactive intestinal polypeptide on the rat vascular system: effects on blood pressure and receptor binding. J. Endocrinol. 1991, 129:69-73.
27. Nishimoto M., Miyakawa H., Wada K., Furuta A. Activation of the VIP/VPAC2 system induces reactive astrocytosis associated with increased expression of glutamate transporters. Brain Res. 2011, 1383:43-53.
28. Ohtaki H., Nakamachi T., Dohi K., Aizawa Y., Takaki A., Hodoyama K., Yofu S., Hashimoto H., Shintani N., Baba A., Kopf M., Iwakura Y., Matsuda K., Arimura A., Shioda S. Pituitary adenylate cyclase-activating polypeptide (PACAP) decreases ischemic neuronal cell death in association with IL-6. Proc. Natl. Acad. Sci. USA 2006, 103:7488-7493.
29. Rangon C.M., Goursaud S., Medja F., Lelievre V., Mounien L., Husson I., Brabet P., Jegou S., Janet T., Gressens P. VPAC2 receptors mediate vasoactive intestinal peptide-induced neuroprotection against neonatal excitotoxic brain lesions in mice. J. Pharmacol. Exp. Ther. 2005, 314:745-752.
30. Reglodi D., Somogyvari-Vigh A., Vigh S., Kozicz T., Arimura A. Delayed systemic administration of PACAP38 is neuroprotective in transient middle cerebral artery occlusion in the rat. Stroke 2000, 31:1411-1417.
31. Reglodi D., Kiss P., Lubics A., Tamas A. Review on the protective effects of PACAP in models of neurodegenerative diseases in vitro and in vivo. Curr. Pharm. Des. 2011, 17:962-972.
32. Shioda S., Ohtaki H., Nakamachi T., Dohi K., Watanabe J., Nakajo S., Arata S., Kitamura S., Okuda H., Takenoya F., Kitamura Y. Pleiotropic functions of PACAP in the CNS: neuroprotection and neurodevelopment. Ann. N. Y. Acad. Sci. 2006, 1070:550-560.
33. Shneider Y., Shtrauss Y., Yadid G., Pinhasov A. Differential expression of PACAP receptors in postnatal rat brain. Neuropeptides. 2010, 44:509-514.
34. Sjoholm A., Nystrom T. Inflammation and the etiology of type 2 diabetes. Diab. Metab. Res. Rev. 2006, 22:4-10.
35. Suzuki K., Yen-Chung H., Toyota T., Goto Y., Hirata Y., Okada K. The significance of nerve sugar levels for the peripheral nerve impairment of spontaneously diabetic GK (Goto-Kakizaki) rats. Diab. Res. 1990, 14:21-25.
36. Takei N., Torres E., Yuhara A., Jongsma H., Otto C., Korhonen L., Abiru Y., Skoglosa Y., Schutz G., Hatanaka H., Sofroniew M.V., Lindholm D. Pituitary adenylate cyclase-activating polypeptide promotes the survival of basal forebrain cholinergic neurons in vitro and in vivo: comparison with effects of nerve growth factor. Eur. J. Neurosci. 2000, 12:2273-2280.
37. Tan, YV., Waschek, JA., 2011. Targeting VIP and PACAP receptor signaling New therapeutic strategies in multiple sclerosis. ASN Neuro.
38. Tsutsumi M., Claus T.H., Liang Y., Li Y., Yang L., Zhu J., Dela Cruz F., Peng X., Chen H., Yung S.L., Hamren S., Livingston J.N., Pan C.Q. A potent and highly selective VPAC2 agonist enhances glucose-induced insulin release and glucose disposal: a potential therapy for type 2 diabetes. Diab. 2002, 51:1453-1460.
39. Vaudry D., Falluel-Morel A., Bourgault S., Basille M., Burel D., Wurtz O., Fournier A., Chow B.K., Hashimoto H., Galas L., Vaudry H. Pituitary adenylate cyclase-activating polypeptide and its receptors: 20 years after the discovery. Pharmacol. Rev. 2009, 61:283-357.
40. White C.M., Ji S., Cai H., Maudsley S., Martin B. Therapeutic potential of vasoactive intestinal peptide and its receptors in neurological disorders. CNS Neurol. Disord Drug Targets 2010, 9:661-666.
41. Witte K., Jacke K., Stahrenberg R., Arlt G., Reitenbach I., Schilling L., Lemmer B. Dysfunction of soluble guanylyl cyclase in aorta and kidney of Goto-Kakizaki rats: influence of age and diabetic state. Nitric Oxide 2002, 6:85-95.
42. Yang J., Zong C.H., Wang W.X., Hu X.D., Li M., Chen G.M. Vasoactive intestinal peptide attenuates apoptosis and iNOS protein expression induced by cerebral ischemia in the rat. Sichuan Da Xue Xue Bao Yi Xue Ban 2008, 39:563-566.
43. Yang J., Song T.B., Zhao Z.H., Qiu S.D., Hu X.D., Chang L. Vasoactive intestinal peptide protects against ischemic brain damage induced by focal cerebral ischemia in rats. Brain Res. 2011, 1398:94-101.
44. Zimmet P., Alberti K.G., Shaw J. Global and societal implications of the diabetes epidemic. Nature 2001, 414:782-787.